P.0067 Lurasidone in the treatment of comorbid anxiety symptoms in bipolar depression

2021 ◽  
Vol 53 ◽  
pp. S48-S49
Author(s):  
M. Tocco ◽  
C. Siu ◽  
A. Pikalov ◽  
J. Goldberg
2019 ◽  
Vol 7 (1) ◽  
Author(s):  
Maximilian Pilhatsch ◽  
Thomas J Stamm ◽  
Petra Stahl ◽  
Ute Lewitzka ◽  
Anne Berghöfer ◽  
...  

Abstract Background Symptoms of anxiety co-occur in a variety of disorders including in depressive episodes of bipolar disorder and in patients with thyrotoxicosis. Treatment of refractory bipolar disorder with supraphysiologic doses of levothyroxine (L-T4) has been shown to improve the phenotypic expression of the disorder and is associated with an increase of circulating thyroid hormones. However, it might be associated with somatic and mental adverse effects. Here we report the investigation of the influence of treatment with supraphysiologic doses of L-T4 on symptoms of anxiety in patients with refractory bipolar depression. Methods Post-hoc analysis from a 6-week, multi-center, randomized, double-blind, placebo-controlled study of the effects of supraphysiologic L-T4 treatment on anxiety symptoms in bipolar depression. Anxiety symptoms were measured weekly with the Hamilton anxiety/somatization factor (HASF) score of the Hamilton Depression Rating Scale (HAMD) and the State- and Trait Anxiety Inventory (STAI). Results Treatment of both groups was associated with a significant reduction in anxiety symptoms (p < 0.001) with no statistical difference between groups (LT-4: from 5.9 (SD = 2.0) at baseline to 3.7 (SD = 2.4) at study end; placebo: from 6.1 (SD = 2.4) at baseline to 4.4 (SD = 2.8) at study end; p = 0.717). Severity of anxiety at baseline did not show a statistically significant correlation to the antidepressive effect of treatment with supraphysiologic doses of L-T4 (p = 0.811). Gender did not show an influence on the reduction of anxiety symptoms (females: from 5.6 (SD = 1.7) at baseline to 3.5 (SD = 2.4) at study end; males: from 6.1 (SD = 2.3) at baseline to 4.0 (SD = 2.4) at study end; p = 0.877). Conclusions This study failed to detect a difference in change of anxiety between bipolar depressed patients treated with supraphysiologic doses of L-T4 or placebo. Comorbid anxiety symptoms should not be considered a limitation for the administration of supraphysiologic doses of L-T4 refractory bipolar depressed patients. Trial registration ClinicalTrials, ClinicalTrials.gov identifier: NCT01528839. Registered 2 June 2012—Retrospectively registered, https://clinicaltrials.gov/ct2/show/study/NCT01528839


2020 ◽  
Vol 260 ◽  
pp. 91-96 ◽  
Author(s):  
Jin Liu ◽  
Qiangli Dong ◽  
Xiaowen Lu ◽  
Jinrong Sun ◽  
Liang Zhang ◽  
...  

2020 ◽  
Vol 10 (7) ◽  
pp. 108 ◽  
Author(s):  
Ozge Ceren Amuk ◽  
Rikinkumar S. Patel

Objective: To evaluate the risk of association between suicidal behaviors and comorbid anxiety disorders in adolescents with bipolar depression. Methods: We conducted a cross-sectional study using the nationwide inpatient sample (NIS) from the United States. This study included 9720 adolescent inpatients with bipolar depression and further grouped by co-diagnosis of anxiety disorders. Logistic regression analysis was used to evaluate the odds ratio (OR) of suicidal behaviors due to comorbid anxiety after controlling demographic confounders and psychiatric comorbidities. Results: Out of total inpatients, 34.8% (n = 3385) had comorbid anxiety disorders with a predominance in females (70.3%) and White patients (67.7%). About 54.1% of inpatients with comorbid anxiety had suicidal behaviors versus 44.6% in the non-anxiety cohort (p < 0.001). Comorbid anxiety disorders were associated with 1.35 times higher odds (95% CI 1.23–1.47, p < 0.001) for suicidal behaviors. Conclusion: Suicidal behaviors are significantly prevalent in bipolar depression adolescents with comorbid anxiety disorders. Anxiety disorders are an independent risk factor in bipolar depression that increase the risk of suicidal behaviors by 35%. This necessitates careful assessment and management of comorbid anxiety disorders in bipolar youth to mitigate suicidality.


2010 ◽  
Vol 181 (1) ◽  
pp. 71-76 ◽  
Author(s):  
Michael Bauer ◽  
Steven M. Berman ◽  
Florian Schlagenhauf ◽  
Bradley Voytek ◽  
Natalie Rasgon ◽  
...  

2011 ◽  
Vol 26 (S2) ◽  
pp. 1956-1956
Author(s):  
D. Meshkat ◽  
A. Kutzelnigg ◽  
C. Eckert ◽  
A. Konstantinidis ◽  
S. Kasper

IntroductionADHD is a highly heritable neurodevelopmental syndrome with significant lifetime risk for psychiatric comorbidities. Several psychiatric conditions are significantly more common in patients with ADHD than in control subjects.MethodsTo evaluate the incidence of comorbid affective disorders, patients with adult ADHD who were first seen at the outpatient clinic of the Department of Psychiatry and Psychotherapy were evaluated for symptoms of major depression, brief recurrent depression, bipolar depression and anxiety disorders. Patients aged between 18 and 75 years were included into the study. All patients were evaluated according to DSM IV TR criteria. So far, from February 2007 until May 2010, 330 patients (192 males and 138 females) were included into the study.ResultsThe mean age of the patients at diagnosis was 33, 7 years for males (range: 18-75) and 35, 9 years for females (range: 18–64). Affective disorders were most frequently diagnosed as comorbid conditions in our patients and occurred in 26% of the patients in our sample. 13% had a minor depressive episode, 7% a major depressive episode and 6% were diagnosed with bipolar disorder. 21% of our patients were diagnosed with one or several comorbid anxiety disorders.ConclusionMost adults with ADHD are not diagnosed properly and therefore remain untreated although they are usually diagnosed and treated for comorbid psychiatric disorders. In the present study, we systematically analyzed comorbid anxiety and depression in a sample of adult ADHD outpatients in order to estimate the incidence of these disorders in an undiagnosed patient population.


2007 ◽  
Vol 104 (1-3) ◽  
pp. 137-146 ◽  
Author(s):  
Mauricio Tohen ◽  
Joseph Calabrese ◽  
Eduard Vieta ◽  
Charles Bowden ◽  
Ana Gonzalez-Pinto ◽  
...  

2009 ◽  
Vol 11 (5) ◽  
pp. 215-225 ◽  
Author(s):  
R. Bruce Lydiard ◽  
Larry Culpepper ◽  
Helena Schiöler ◽  
Urban Gustafsson ◽  
Björn Paulsson

2021 ◽  
pp. ebmental-2021-300259
Author(s):  
Sharleny Stanislaus ◽  
Klara Coello ◽  
Hanne Lie Kjærstad ◽  
Kimie Stefanie Ormstrup Sletved ◽  
Ida Seeberg ◽  
...  

BackgroundAround 40% of patients with bipolar disorder (BD) additionally have anxiety disorder. The prevalence of anxiety in patients with newly diagnosed BD and their first-degree relatives (UR) has not been investigated.ObjectiveTo investigate (1) the prevalence of a comorbid anxiety diagnosis in patients with newly diagnosed BD and their UR, (2) sociodemographic and clinical differences between patients with and without a comorbid anxiety diagnosis and (3) the association between smartphone-based patient-reported anxiety and observer-based ratings of anxiety and functioning, respectively.MethodsWe recruited 372 patients with BD and 116 of their UR. Daily smartphone-based data were provided from 125 patients. SCAN was used to assess comorbid anxiety diagnoses.FindingsIn patients with BD, the prevalence of a comorbid anxiety disorder was 11.3% (N=42) and 10.3% and 5.9% in partial and full remission, respectively. In UR, the prevalence was 6.9%. Patients with a comorbid anxiety disorder had longer illness duration (p=0.016) and higher number of affective episodes (p=0.011). Smartphone-based patient-reported anxiety symptoms were associated with ratings of anxiety and impaired functioning (p<0.001).LimitationsThe SCAN interviews to diagnose comorbid anxiety disorder were carried out regardless of the participants’ mood state.Clinical implicationsThe lower prevalence of anxiety in newly diagnosed BD than in later stages of BD indicates that anxiety increases with progression of BD. Comorbid anxiety seems associated with poorer clinical outcomes and functioning and smartphones are clinically useful for monitoring anxiety symptoms.Trial registration numberClinicalTrials.gov Registry (NCT02888262).


2007 ◽  
Vol 190 (4) ◽  
pp. 344-349 ◽  
Author(s):  
Carmen Andreescu ◽  
Eric J. Lenze ◽  
Mary Amanda Dew ◽  
Amy E. Begley ◽  
Benoit H. Mulsant ◽  
...  

BackgroundComorbid anxiety is common in depressive disorders in both middle and late life, and it affects response to antidepressant treatment.AimsTo examine whether anxiety symptoms predict acute and maintenance (2 years) treatment response in late-life depression.MethodData were drawn from a randomised double-blind study of pharmacotherapy and interpersonal psychotherapy for patients age 70 years and over with major depression. Anxiety symptoms were measured using the Brief Symptom Inventory. Survival analysis tested the effect of pre-treatment anxiety on response and recurrence.ResultsPatients with greater pre-treatment anxiety took longer to respond to treatment and had higher rates of recurrence. Actuarial recurrence rates were 29% (pharmacotherapy, lower anxiety), 58% (pharmacotherapy, higher anxiety), 54% (placebo, lower anxiety) and 81% (placebo, higher anxiety).ConclusionsImproved identification and management of anxiety in late-life depression are needed to achieve response and stabilise recovery.


Sign in / Sign up

Export Citation Format

Share Document